Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response

Zhanzhan Li; Yanyan Li; Yifu Tian; Na Li; Liangfang Shen; Yajie Zhao

doi:10.3389/fimmu.2023.1170539

Pan-cancer analysis identifies the correlations of Thymosin Beta 10 with predicting prognosis and immunotherapy response

Front Immunol. 2023 May 18:14:1170539. doi: 10.3389/fimmu.2023.1170539. eCollection 2023.

Authors

Zhanzhan Li¹, Yanyan Li², Yifu Tian³, Na Li¹, Liangfang Shen¹, Yajie Zhao^{4

5}

Affiliations

¹ Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
² Department of Nursing, Xiangya Hospital, Central South University, Changsha, Hunan, China.
³ Department of Pathology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
⁴ Department of Nuclear Medicine, Xiangya Hospital, Central South University, Changsha, Hunan, China.
⁵ National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.

Abstract

Introduction: The biological function and prognosis roles of thymosin β(TMSB) 10 are still unclear in pan-cancer.

Methods: We retrieved The Cancer Genome Atlas and Genotype-tissue expression datasets to obtain the difference of TMSB10 expression between pan-cancer and normal tissues, and analyzed the biological function and prognosis role of TMSB10 in pan-cancer by using cBioPortal Webtool.

Results: The expression of TMSB10 in tumor tissues was significantly higher than normal tissues, and showed the potential ability to predict the prognosis of patients in Pan-cancer. It was found that TMSB10 was significantly correlated with tumor microenvironment, immune cell infiltration and immune regulatory factor expression. TMSB10 is involved in the regulation of cellular signal transduction pathways in a variety of tumors, thereby mediating the occurrence of tumor cell invasion and metastasis. Finally, TMSB10 can not only effectively predict the anti-PD-L1 treatment response of cancer patients, but also be used as an important indicator to evaluate the sensitivity of chemotherapy. In vitro, low expression of TMSB10 inhibited clonogenic formation ability, invasion, and migration in glioma cells. Furthermore, TMSB10 may involve glioma immune regulation progression by promoting PD-L1 expression levels via activating STAT3 signaling pathway.

Conclusions: Our results show that TMSB10 is abnormally expressed in tumor tissues, which may be related to the infiltration of immune cells in the tumor microenvironment. Clinically, TMSB10 is not only an effective prognostic factor for predicting the clinical treatment outcome of cancer patients, but also a promising biomarker for predicting the effect of tumor immune checkpoint inhibitors (ICIs) and chemotherapy in some cancers.

Keywords: TMSB10; immune infiltration; immunotherapy; pan-cancer; prognosis.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Glioma*
Humans
Immune Checkpoint Inhibitors
Immunotherapy
Prognosis
Thymosin* / genetics
Tumor Microenvironment / genetics

Substances

Thymosin
Immune Checkpoint Inhibitors

Grants and funding

This study was supported by the National Natural Science Foundation of China (ZL: No.82003239);, and National key clinical specialty (2209090720).